FOLH1 and neoplasm: This situation resulted in equal tumor-to-kidney dose ratios for [177Lu]Lu-Ibu-DAB-PSMA and [177Lu]Lu-PSMA-ALB-56 (13 ± 3 and 13 ± 5, respectively) which was, however, fivefold lower than for [177Lu]Lu-PSMA-617 (64 ± 22).